Natural HLA-B*2705 Protein Ligands with Glutamine as Anchor Motif

Background: HLA-B27 is strongly associated with ankylosing spondylitis (AS). Results: A change in the position (P) 2 anchor motif was detected in the 3% of HLA-B27 ligands identified, which showed significant homology to pathogenic bacterial sequences. Conclusion: Unusual HLA-B*2705 ligands bind with different conformations to both AS-associated and non-AS-associated HLA-B27 subtypes. Significance: This could be sufficient to initiate autoimmune damage in patients with AS-associated subtypes. The presentation of short viral peptide antigens by human leukocyte antigen (HLA) class I molecules on cell surfaces is a key step in the activation of cytotoxic T lymphocytes, which mediate the killing of pathogen-infected cells or initiate autoimmune tissue damage. HLA-B27 is a well known class I molecule that is used to study both facets of the cellular immune response. Using mass spectrometry analysis of complex HLA-bound peptide pools isolated from large amounts of HLA-B*2705+ cells, we identified 200 naturally processed HLA-B*2705 ligands. Our analyses revealed that a change in the position (P) 2 anchor motif was detected in the 3% of HLA-B*2705 ligands identified. B*2705 class I molecules were able to bind these six GlnP2 peptides, which showed significant homology to pathogenic bacterial sequences, with a broad range of affinities. One of these ligands was able to bind with distinct conformations to HLA-B27 subtypes differentially associated with ankylosing spondylitis. These conformational differences could be sufficient to initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes. Therefore, these kinds of peptides (short, with GlnP2, and similar low affinity to all HLA-B27 subtypes tested but with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be excluded from future researches involving potential arthritogenic peptides.

[1]  A. McMichael,et al.  Recognition of HLA-B27 and related antigen by a monoclonal antibody. , 1982, Human immunology.

[2]  M. Marcilla,et al.  Peptides: the cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis. , 2008, Tissue antigens.

[3]  Ilan Beer,et al.  Multiple, Non-conserved, Internal Viral Ligands Naturally Presented by HLA-B27 in Human Respiratory Syncytial Virus-infected Cells* , 2010, Molecular & Cellular Proteomics.

[4]  A. Goldberg,et al.  Proteolysis and class I major histocompatibility complex antigen presentation , 1999, Immunological reviews.

[5]  J. A. López de Castro,et al.  Structure and diversity of HLA-B27-specific T cell epitopes. Analysis with site-directed mutants mimicking HLA-B27 subtype polymorphism. , 1990, Journal of immunology.

[6]  N. Shastri,et al.  Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. , 2002, Annual review of immunology.

[7]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[8]  Rosa Sorrentino,et al.  Dual, HLA-B27 Subtype-dependent Conformation of a Self-peptide , 2004, The Journal of experimental medicine.

[9]  J. Albar,et al.  Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. , 1996, Tissue antigens.

[10]  P. de León,et al.  An Endogenous HIV Envelope-derived Peptide without the Terminal NH3+ Group Anchor Is Physiologically Presented by Major Histocompatibility Complex Class I Molecules* , 2004, Journal of Biological Chemistry.

[11]  J. Villadangos,et al.  Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. , 1994, Journal of immunology.

[12]  M. Vázquez,et al.  HLA-B27: a registry of constitutive peptide ligands. , 2004, Tissue antigens.

[13]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[14]  Y. Shoenfeld,et al.  Subcutaneous T-cell lymphoma in a patient with rheumatoid arthritis not treated with cytotoxic agents , 1997, Clinical Rheumatology.

[15]  Heinz Fabian,et al.  HLA-B27 heavy chains distinguished by a micropolymorphism exhibit differential flexibility. , 2010, Arthritis and rheumatism.

[16]  Eric O Long,et al.  Direct binding of a soluble natural killer cell inhibitory receptor to a soluble human leukocyte antigen-Cw4 class I major histocompatibility complex molecule. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R D Sturrock,et al.  Ankylosing spondylitis and HL-A 27. , 1973, Lancet.

[18]  Morten Nielsen,et al.  CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. , 2007, Vaccine.

[19]  Ilan Beer,et al.  The HLA-B*2705 peptidome. , 2010, Arthritis and rheumatism.

[20]  R. Hoffman,et al.  Immune pathogenesis of Mixed Connective Tissue Disease: a short analytical review. , 2008, Clinical immunology.

[21]  W. Graninger,et al.  Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. , 1995, Arthritis and rheumatism.

[22]  A. Langerak,et al.  Clonal identity between skin and synovial tissue in a case of mycosis fungoides with polyarthritis. , 2004, Journal of the American Academy of Dermatology.

[23]  E. Camafeita,et al.  Identification of Novel HLA-B27 Ligands Derived from Polymorphic Regions of Its Own or Other Class I Molecules Based on Direct Generation by 20 S Proteasome* , 2001, The Journal of Biological Chemistry.

[24]  R. Hammer,et al.  Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. , 2006, Arthritis and rheumatism.

[25]  A. Marina,et al.  Major Histocompatibility Complex Class I Molecules Bind Natural Peptide Ligands Lacking the Amino-terminal Binding Residuein Vivo * , 2001, The Journal of Biological Chemistry.

[26]  L. Espinoza,et al.  HLA-B27-Associated Reactive Arthritis: Pathogenetic and Clinical Considerations , 2004, Clinical Microbiology Reviews.

[27]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[28]  A. van Leeuwen,et al.  Guilt by association: HLA-B27 and ankylosing spondylitis. , 1990, Immunology today.

[29]  P. van Endert,et al.  A Long N-terminal-extended Nested Set of Abundant and Antigenic Major Histocompatibility Complex Class I Natural Ligands from HIV Envelope Protein* , 2006, Journal of Biological Chemistry.

[30]  M. A. Saper,et al.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens , 1987, Nature.

[31]  Dean R. Madden,et al.  The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC , 1992, Cell.

[32]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[33]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[34]  Paul Weston,et al.  Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility , 2011, Nature Genetics.

[35]  S. Chubinskaya,et al.  ADAM-10 Protein Is Present in Human Articular Cartilage Primarily in the Membrane-bound Form and Is Upregulated in Osteoarthritis and in Response to IL-1α in Bovine Nasal Cartilage , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[36]  J. A. López de Castro,et al.  Peptide-presenting similarities among functionally distant HLA-B27 subtypes revealed by alloreactive T lymphocytes of unusual specificity. , 1992, Journal of immunology.

[37]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[38]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[39]  P. Croucher,et al.  Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. , 1997, Biochemical and biophysical research communications.

[40]  A. Marina,et al.  The Peptide Repertoires of HLA-B27 Subtypes Differentially Associated to Spondyloarthropathy (B*2704 and B*2706) Differ by Specific Changes at Three Anchor Positions* , 2002, The Journal of Biological Chemistry.

[41]  P. Cresswell,et al.  NK susceptibility varies inversely with target cell class I HLA antigen expression. , 1987, Journal of immunology.

[42]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.

[43]  R. Inman,et al.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis , 2012, Annals of the rheumatic diseases.

[44]  Ilan Beer,et al.  Improving large‐scale proteomics by clustering of mass spectrometry data , 2004, Proteomics.